FDA regulation of cardiovascular devices and opportunities for improvement

被引：12

作者：

Dhruva, Sanket S. ^{[1
]}

Redberg, Rita F. ^{[2
]}

机构：

[1] Univ Calif Davis, Dept Internal Med, Div Cardiol, Davis, CA 95616 USA

[2] Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA

来源：

JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY | 2013年 / 36卷 / 02期

关键词：

Cardiovascular devices; Cardiovascular disease; FDA; Medical device regulation; IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; MEDICAL DEVICES; POSTMARKETING SURVEILLANCE; PREMARKET APPROVAL; THERAPY; TRIALS; WOMEN; OUTCOMES; FAILURE; RECALLS;

D O I：

10.1007/s10840-012-9767-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Medical devices are of increasing importance in cardiovascular disease and have made important contributions to patient care. These devices continue to evolve with increasing complexity. FDA regulation of medical devices involves increased stringency for higher risk and novel devices. However, there are some current opportunities to strengthen the FDA's pre-approval regulatory process and improve post-marketing surveillance. This article reviews FDA regulation of cardiovascular devices and offers suggestions for strengthening the process while focusing on examples relevant to cardiac electrophysiologists.

引用

页码：99 / 105

页数：7

共 50 条

[1] FDA regulation of cardiovascular devices and opportunities for improvement
Sanket S. Dhruva
Rita F. Redberg
Journal of Interventional Cardiac Electrophysiology, 2013, 36 : 99 - 105
[2] FDA'S Perspectives on Cardiovascular Devices
Chen, Eric A.
Patel-Raman, Sonna M.
O'Callaghan, Kathryn
Hillebrenner, Matthew G.
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2009, 2 (02) : 143 - 146
[3] FDA’S Perspectives on Cardiovascular Devices
Eric A. Chen
Sonna M. Patel-Raman
Kathryn O’Callaghan
Matthew G. Hillebrenner
Journal of Cardiovascular Translational Research, 2009, 2 : 143 - 146
[4] Gender Bias in Studies for FDA Premarket Approval of Cardiovascular Devices
Dhruva S.S.
Cullen E.B.
Redberg R.F.
Current Cardiovascular Risk Reports, 2014, 8 (7) : 1 - 5
[5] Strength of Study Evidence Examined by the FDA in Premarket Approval of Cardiovascular Devices
Dhruva, Sanket S.
Bero, Lisa A.
Redberg, Rita F.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (24): : 2679 - 2685
[6] Physicians' Perspectives On FDA Regulation Of Drugs And Medical Devices: A National Survey
Dhruva, Sanket S.
Kesselheim, Aaron S.
Woloshin, Steven
Ji, Robin Z.
Lu, Zhigang
Darrow, Jonathan J.
Redberg, Rita F.
HEALTH AFFAIRS, 2024, 43 (01) : 27 - 35
[7] Epidemiology of Cardiovascular Disease in China and Opportunities for Improvement
Du, Xin
Patel, Anushka
Anderson, Craig S.
Dong, Jianzeng
Ma, Changsheng
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (24) : 3135 - 3147
[8] FDA REGULATION OF DENTAL DEVICES - PAST, PRESENT, AND FUTURE
TYLENDA, CA
JOURNAL OF PUBLIC HEALTH DENTISTRY, 1992, 52 (06) : 364 - 368
[9] Evidence Strength in FDA Premarket Approval of Cardiovascular Devices Reply
Redberg, Rita F.
Dhruva, Sanket S.
Bero, Lisa A.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (16): : 1600 - 1601
[10] BAYESIAN STATISTICS IN MEDICAL DEVICES: INNOVATION SPARKED BY THE FDA
Campbell, Gregory
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2011, 21 (05) : 871 - 887

← 1 2 3 4 5 →